## FDA Internally Concludes UniQure's Huntington's Therapy Shows No Benefit, Blocks Marketing Application
A senior FDA official, speaking anonymously, has revealed that the agency has concluded the experimental Huntington's disease treatment from UniQure provides no therapeutic benefit to patients based on the existing clinical data. This internal assessment directly explains the FDA's decision to block the company from submitting a marketing application for the gene therapy. The official stated, "Agency reviewers 'are not convinced there's any therapeutic benefit of the product.'" They further clarified the agency's position, adding, "If we felt there was any therapeutic benefit, we, of course, would approve it. But they're not persuaded." This disclosure provides a rare, candid look into the FDA's internal scientific skepticism regarding a high-profile, late-stage gene therapy, highlighting a significant regulatory hurdle for UniQure and impacting the prospects for patients awaiting new treatments for the devastating neurodegenerative disease.
---
- **Source**: 
- **Sector**: The Lab
- **Tags**: huntington's disease, gene therapy, fda, uniqure
- **Credibility**: unverified
- **Published**: 2026-03-06 16:43:55
- **ID**: 2670
- **URL**: https://whisperx.ai/en/intel/2670